NCT07360275进行中（未招募）2 期
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of VCT220 in Participants With Hypertension and Obesity or Overweight.
Vincentage Pharma Co., Ltd2 个研究点 分布在 1 个国家目标入组 160 人开始时间: 2026年3月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 160
- 试验地点
- 2
- 主要终点
- Change from baseline in office seated systolic blood pressure (SBP) at Week 20
研究概览
简要总结
The purpose of this study is to explore the safety and efficacy of VCT220 for the treatment of hypertension in participants with obesity or overweight.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female participants aged 18 to 75 years (inclusive) at the time of screening.
- •Body mass index (BMI) ≥ 24 kg/m² at screening.
- •Diagnosed with primary hypertension, with office seated systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg at both screening and baseline.
- •Either treatment-naïve to antihypertensive therapy for ≥ 30 days prior to screening, or receiving a stable dose for ≥ 30 days of one or two of the following classes of antihypertensive medications: renin-angiotensin system inhibitors (ARB/ACEI), calcium channel blockers (CCB), or diuretics.
- •Has at least one self-reported history of unsuccessful weight loss through dietary control.
- •Willing and able to maintain a stable residence and remain contactable throughout the study, and to adhere to regular lifestyle routines as well as dietary and exercise management during the trial.
- •Has a full understanding of the study procedures, is able to communicate effectively with the investigator, understands and is willing to comply with all study requirements, and voluntarily provides written informed consent.
排除标准
- •Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2).
- •History of or current secondary hypertension.
- •Office seated systolic blood pressure (SBP) ≥ 170 mmHg and/or diastolic blood pressure (DBP) ≥ 110 mmHg at screening or baseline, or presence of a hypertensive emergency.
- •A decrease in office seated SBP of ≥ 20 mmHg or a decrease in office seated DBP of ≥ 10 mmHg at baseline compared with screening.
- •Presence of orthostatic hypotension at screening, defined as a decrease in office SBP of ≥ 15 mmHg or DBP of ≥ 7 mmHg upon transition from the seated to standing position.
- •A difference of ≥ 20 mmHg in office seated SBP between the left and right upper arms at screening or baseline.
- •Treatment with any marketed or investigational drug with a glucagon-like peptide-1 (GLP-1) receptor agonist mechanism within 1 year prior to screening.
- •Self-reported or documented body weight change of ≥ 5 kg within 3 months prior to screening.
- •History of or current type 1 or type 2 diabetes mellitus.
- •History of or current malignancy within the past 5 years, except for adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix.
- •History of or current major cardiovascular or cerebrovascular disease.
- •History of or current severe gastrointestinal disease or prior major gastrointestinal surgery.
- •Clinically significant active or unstable severe major depressive disorder or other severe psychiatric disorders within 2 years prior to screening; or any history of suicide attempt.
- •Patient Health Questionnaire-9 (PHQ-9) score ≥ 15 at screening, or a positive response to Item
- •Pregnant or breastfeeding women; or men or women of childbearing potential who are unwilling to use highly effective contraception throughout the study and for 3 months after the last dose, or who plan to conceive, donate sperm, or donate oocytes during this period; or women with a positive pregnancy test at screening.
研究组 & 干预措施
VCT220 160mg (1)
Experimental
Participants will receive VCT220 orally everyday. Starting from 20mg and maintaining at 160mg
干预措施: VCT220 Tablet (Drug)
VCT220 160mg (2)
Experimental
Participants will receive VCT220 orally everyday. Starting from 40mg and maintaining at 160mg
干预措施: VCT220 Tablet (Drug)
VCT220 80mg
Experimental
Participants will receive VCT220 orally everyday. Starting from 20mg and maintaining at 80mg
干预措施: VCT220 Tablet (Drug)
Placebo
Placebo Comparator
Participants will receive placebo orally.
干预措施: VCT220 Placebo Tablet (Drug)
结局指标
主要结局
Change from baseline in office seated systolic blood pressure (SBP) at Week 20
时间窗: From baseline to week 20
Measured In mmHg
次要结局
- Change from baseline in office seated diastolic blood pressure (DBP) at Week 20(From baseline to week 20)
- Change from baseline in 24-hour ambulatory blood pressure monitoring (ABPM) systolic blood pressure and diastolic blood pressure at Week 20(From baseline to week 20)
- Proportion of participants achieving the standard blood pressure target (< 140/90 mmHg) based on office seated blood pressure at Week 20(From baseline to week 20)
- Proportion of participants achieving the intensive blood pressure target (< 130/80 mmHg) based on office seated blood pressure at Week 20(From baseline to week 20)
- Changes in body weight at week 20(From baseline to week 20)
- Adverse events, including treatment-emergent adverse events (TEAEs), serious adverse events (SAEs)(From baseline to week 20)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
3 期
A Study of SHR-1918 In Participants With HypertriglyceridemiaHypertriglyceridemiaNCT07349615Beijing Suncadia Pharmaceuticals Co., Ltd360
招募中
2 期
A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)Active Systemic Lupus ErythematosusNCT07311200InventisBio Co., Ltd120
进行中（未招募）
2 期
Taldefgrobep Alfa in Adults With Overweight and ObesityOverweightObesityNCT07281495Biohaven Therapeutics Ltd.150
招募中
3 期
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's DiseaseEarly Parkinson’s Disease2025-521113-13-00Biohaven Therapeutics Ltd.349
已完成
3 期
A prospective, randomized, double-blind placebo-controlled multicentre study with mannan-conjugated birch pollen allergoids administered subcutaneously to adolescent and adult patients with birch pollen-induced allergic rhinitis or rhinoconjunctivitis.Birch pollen induced allergic rhinitis or rhinoconjunctivitis2023-508013-16-00CCDRD Cooperative Clinical Drug Research and Development AG, Inmunotek S.L., ClinCompetence Cologne GmbH600